$MGNX
MacroGenics Inc Stock $mgnx

$mgnx Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000112534524000148 Filed on August 06, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$110.7M	$10.80M
YoY Change	964.81%	-17.81%
Cost Of Revenue	$168.0K	$176.0K
YoY Change	97.65%	-31.78%
Gross Profit	$110.5M	$10.62M
YoY Change	971.96%	-17.53%
Gross Profit Margin	99.85%	98.37%
Selling, General & Admin	$14.10M	$14.42M
YoY Change	13.74%	5.34%
% of Gross Profit	12.76%	135.8%
Research & Development	$40.54M	$51.73M
YoY Change	34.56%	19.67%
% of Gross Profit	36.68%	487.07%
Depreciation & Amortization	$1.835M	$1.811M
YoY Change	-5.9%	-35.6%
% of Gross Profit	1.66%	17.05%
Operating Expenses	$40.54M	$51.73M
YoY Change	34.56%	19.67%
Operating Profit	$54.19M	-$58.18M
YoY Change	-252.64%	29.4%
Interest Expense	$0.00	$6.000K
YoY Change		-99.22%
% of Operating Profit	0.0%
Other Income/Expense, Net	$2.118M	$2.523M
YoY Change	-31.68%	10.9%
Pretax Income	$56.31M	-$55.66M
YoY Change	219.94%	-196.86%
Income Tax
% Of Pretax Income
Net Earnings	$56.31M	-$55.66M
YoY Change	220.78%	-196.86%
Net Earnings / Revenue	50.86%	-515.55%
Basic Earnings Per Share	$0.90	-$0.89
Diluted Earnings Per Share	$0.90	-$0.89
COMMON SHARES
Basic Shares Outstanding	62.72M shares	62.63M shares
Diluted Shares Outstanding	62.87M shares	62.66M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$200.4M	$140.4M
YoY Change	-21.86%	-41.6%
Cash & Equivalents	$179.6M	$83.93M
Short-Term Investments	$20.74M	$56.44M
Other Short-Term Assets	$9.839M	$9.273M
YoY Change	15.75%	43.21%
Inventory	$3.244M	$1.115M
Prepaid Expenses
Receivables	$8.750M	$6.191M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$222.2M	$157.0M
YoY Change	-23.73%	-38.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$19.10M	$20.38M
YoY Change	-15.61%	-15.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.185M	$1.186M
YoY Change	-14.56%	-14.43%
Total Long-Term Assets	$42.30M	$44.19M
YoY Change	-13.07%	-13.32%
TOTAL ASSETS
Total Short-Term Assets	$222.2M	$157.0M
Total Long-Term Assets	$42.30M	$44.19M
Total Assets	$264.5M	$201.1M
YoY Change	-22.2%	-34.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.613M	$5.236M
YoY Change	100.21%	37.97%
Accrued Expenses	$24.64M	$24.45M
YoY Change	-3.27%	-11.2%
Deferred Revenue	$23.31M	$23.82M
YoY Change	25.42%	146.28%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$59.31M	$57.91M
YoY Change	15.63%	28.24%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$258.0K	$258.0K
YoY Change	0.0%	0.0%
Total Long-Term Liabilities	$258.0K	$258.0K
YoY Change	0.0%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$59.31M	$57.91M
Total Long-Term Liabilities	$258.0K	$258.0K
Total Liabilities	$144.4M	$143.3M
YoY Change	-1.07%	6.87%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.154B	-$1.211B
YoY Change	9.24%	12.69%
Common Stock	$1.274B	$1.268B
YoY Change	1.89%	1.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$120.1M	$57.82M
YoY Change
Total Liabilities & Shareholders Equity	$264.5M	$201.1M
YoY Change	-22.2%	-34.19%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	$56.31M	-$55.66M
YoY Change	220.78%	-196.86%
Depreciation, Depletion And Amortization	$1.835M	$1.811M
YoY Change	-5.9%	-35.6%
Cash From Operating Activities	$60.16M	-$44.49M
YoY Change	-270.67%	2029.49%
INVESTING ACTIVITIES
Capital Expenditures	$592.0K	$1.035M
YoY Change	20.82%	261.89%
Acquisitions
YoY Change
Other Investing Activities	$36.19M	$48.47M
YoY Change	-209.6%	-142.82%
Cash From Investing Activities	$35.60M	$47.44M
YoY Change	-206.17%	-141.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-68.00K	625.0K
YoY Change	-100.14%	959.32%
NET CHANGE
Cash From Operating Activities	60.16M	-44.49M
Cash From Investing Activities	35.60M	47.44M
Cash From Financing Activities	-68.00K	625.0K
Net Change In Cash	95.69M	3.577M
YoY Change	-607.12%	-103.1%
FREE CASH FLOW
Cash From Operating Activities	$60.16M	-$44.49M
Capital Expenditures	$592.0K	$1.035M
Free Cash Flow	$59.57M	-$45.52M
YoY Change	-266.68%	1816.63%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	446000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	371000	usd
CY2024Q2	mgnx	Cost Of Manufacturing Services CostOfManufacturingServices	2647000	usd
CY2023Q2	mgnx	Cost Of Manufacturing Services CostOfManufacturingServices	919000	usd
	mgnx	Cost Of Manufacturing Services CostOfManufacturingServices	4493000	usd
	mgnx	Cost Of Manufacturing Services CostOfManufacturingServices	4329000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	51732000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	121020000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-58181000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-44962000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-111931000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-83388000	usd
CY2024Q2	mgnx	Gain On Royalty Monetization Arrangement GainOnRoyaltyMonetizationArrangement	0	usd
CY2023Q2	mgnx	Gain On Royalty Monetization Arrangement GainOnRoyaltyMonetizationArrangement	100930000	usd
	mgnx	Gain On Royalty Monetization Arrangement GainOnRoyaltyMonetizationArrangement	0	usd
	mgnx	Gain On Royalty Monetization Arrangement GainOnRoyaltyMonetizationArrangement	100930000	usd
CY2024Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2523000	usd
CY2023Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2275000	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	5216000	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	3348000	usd
CY2024Q2	us-gaap	Interest Expense InterestExpense	6000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	774000	usd
	us-gaap	Interest Expense InterestExpense	1139000	usd
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.92
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.73
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.31
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62663677	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61880096	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62477108	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62663677	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62261646	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62477108	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62030710	shares
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	152613000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5512000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	142013000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-107854000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2254000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	12204000	usd
	mgnx	Gain On Royalty Monetization Arrangement GainOnRoyaltyMonetizationArrangement	0	usd
	mgnx	Non Cash Interest Expense Recognized NonCashInterestExpenseRecognized	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4176000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-106000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-673000	usd
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-1104000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-513000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1259000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14922000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	148040000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	63250000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	645000	usd
	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	54000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-85381000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	616000	usd
	mgnx	Proceedsfrom Stock Options Exercised And Espp Purchases ProceedsfromStockOptionsExercisedAndESPPPurchases	227000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	165000	usd
	mgnx	Principal Payments On Royalty Monetization Arrangement PrincipalPaymentsOnRoyaltyMonetizationArrangement	156000	usd
	mgnx	Net Proceeds From Sale Of Future Royalties NetProceedsFromSaleOfFutureRoyalties	99655000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	100177000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-126000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108884000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	83932000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108758000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	177000	usd
CY2024Q2	us-gaap	Revenues Revenues	10797000	usd
CY2023Q2	us-gaap	Revenues Revenues	13136000	usd
	us-gaap	Revenues Revenues	19901000	usd
	us-gaap	Revenues Revenues	37632000	usd
CY2024Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	176000	usd
CY2023Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	258000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	43229000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	97760000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	89101000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14423000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13692000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29133000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	27219000	usd
CY2024Q2	us-gaap	Costs And Expenses CostsAndExpenses	68978000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	131832000	usd
	us-gaap	Interest Expense InterestExpense	1430000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-55664000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	57469000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-107854000	usd
	us-gaap	Net Income Loss NetIncomeLoss	19460000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	11000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-80000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-18000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-67000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-55653000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	57389000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-107872000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	19393000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.89
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.93
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.73
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.31
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.89
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4788000	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	13000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-38009000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	109268000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	7000	usd
CY2023Q2	us-gaap	Costs And Expenses CostsAndExpenses	58098000	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61845151	shares
CY2024Q1	mgnx	Stock Issued During Period Value Stock Plan Activity StockIssuedDuringPeriodValueStockPlanActivity	248000	usd
CY2024Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-29000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-52190000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	106154000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6693000	usd
CY2024Q2	mgnx	Stock Issued During Period Value Stock Plan Activity StockIssuedDuringPeriodValueStockPlanActivity	625000	usd
CY2024Q2	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	11000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-55664000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	57819000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	617000	usd
CY2023Q1	mgnx	Stock Issued During Period Value Stock Plan Activity StockIssuedDuringPeriodValueStockPlanActivity	-154000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4436000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	235000	usd
CY2023Q2	mgnx	Stock Issued During Period Value Stock Plan Activity StockIssuedDuringPeriodValueStockPlanActivity	216000	usd
CY2023Q2	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-80000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	57469000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	171544000	usd
	us-gaap	Net Income Loss NetIncomeLoss	19460000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3652000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5795000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1404000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9224000	usd
	mgnx	Gain On Royalty Monetization Arrangement GainOnRoyaltyMonetizationArrangement	100930000	usd
	mgnx	Non Cash Interest Expense Recognized NonCashInterestExpenseRecognized	1430000	usd
	mgnx	Operating Lease Noncash Expense OperatingLeaseNoncashExpense	1228000	usd
	mgnx	Operating Lease Noncash Expense OperatingLeaseNoncashExpense	1834000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-21000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-339000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-49812000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-8000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3686000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-200000	usd
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-1243000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	450000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1293000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	86000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1573000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-90128000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	58505000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	133150000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2494000	usd
	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	80000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	72231000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	mgnx	Proceedsfrom Stock Options Exercised And Espp Purchases ProceedsfromStockOptionsExercisedAndESPPPurchases	3270000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2397000	usd
	mgnx	Principal Payments On Royalty Monetization Arrangement PrincipalPaymentsOnRoyaltyMonetizationArrangement	0	usd
	mgnx	Net Proceeds From Sale Of Future Royalties NetProceedsFromSaleOfFutureRoyalties	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	873000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17024000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100956000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	36000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	56463000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	23000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	56440000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	128855000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	16000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	22000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	128849000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2024Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	261000	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1115000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	960000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	1115000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1221000	usd
CY2024Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3100000	usd
CY2017Q2	mgnx	Share Based Compensation Arrangement By Share Based Payment Award Offering Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod	P6M
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6651000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4391000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12204000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9224000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y21D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M17D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12223637	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	15.11
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M12D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1903482	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	16.45
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	330641	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	9.43
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	119105	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	11.80
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	171485	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	22.83
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13505888	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	15.37
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M12D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	160000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	8404002	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	18.11
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y4M24D
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	111000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	12415387	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	15.78
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y6M
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	148000	usd
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	30100000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y6M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.99
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.78
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2615000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	56000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3117000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	36000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	7344000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	3533000	usd
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001125345-24-000148-index-headers.html	Edgar Link	pending
0001125345-24-000148-index.html	Edgar Link	pending
0001125345-24-000148.txt	Edgar Link	pending
0001125345-24-000148-xbrl.zip	Edgar Link	pending
exhibit31-1q22024.htm	Edgar Link	pending
exhibit31-2q22024.htm	Edgar Link	pending
exhibit32-1q22024.htm	Edgar Link	pending
exhibit32-2q22024.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mgnx-20240630.htm	Edgar Link	pending
mgnx-20240630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
mgnx-20240630_cal.xml	Edgar Link	unprocessable
mgnx-20240630_def.xml	Edgar Link	unprocessable
mgnx-20240630_lab.xml	Edgar Link	unprocessable
mgnx-20240630_pre.xml	Edgar Link	unprocessable
mgnx-20240630_htm.xml	Edgar Link	completed
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MGNX
MacroGenics Inc Stock $mgnx

2024 Q3 Form 10-Q Financial Statement

#000112534524000148 Filed on August 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGNX MacroGenics Inc Stock $mgnx

2024 Q3 Form 10-Q Financial Statement

#000112534524000148 Filed on August 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGNX
MacroGenics Inc Stock $mgnx